An observational study in Overactive Bladder (OAB), Urgency Urinary Incontinence and Non-obstructive Urinary Retention, sponsored by Fundación Santa Fe de Bogota. Not yet recruiting at 1 site in Colombia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by Fundación Santa Fe de Bogota · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Urinary Bladder, Overactive with a site in Colombia — 2 open to participants now, 2 under way, none of them phase 3. Urinary Bladder, Overactive · Colombia.
Among the 11 studies in Urinary Bladder, Overactive with a site in Colombia, this one is the only one that started in 2026, is one of 2 observational ones, and was the 11th registered.
861 studies on the registry are indexed under Urinary Bladder, Overactive; 128 are open to participants now.
Browse Urinary Bladder, Overactive studies →2 of the 11 studies in Urinary Bladder, Overactive with a site in Colombia are open now. Recruiting first, the newest first:
InMode MD Ltd. · Sites in Colombia, United States
Ages 21–80 · Women only
A study can be open while its sites in Colombia have not opened yet or have stopped. Only those recruiting at a site in Colombia →
Of the 75 Urinary Bladder, Overactive studies recruiting now, 45 (60%) set no upper age limit and 16 (21%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,700 is above the median of 120 across 169 observational studies indexed under Urinary Bladder, Overactive.
Median enrollment 947 across the 9 interventional studies, 1,700 across the 1 observational. Of the 8 that completed or were terminated, 7 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 7 most frequent:
Fundación Santa Fe de Bogota is the lead sponsor of 27 studies on the registry; 11 are open to participants now.
Fundación Santa Fe de Bogota has 1 study filed under Urinary Bladder, Overactive — fewer than ten, so there is no comparison to draw.
1 of the studies in Urinary Bladder, Overactive with a site in Colombia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07856238Fundación Santa Fe de BogotaLong-Term Effectiveness and Safety of Sacral Neuromodulation With InterStim for Lower Urinary Tract Dysfunction | 2027-05-01 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Urinary Bladder, Overactive with a site in Colombia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This observational study will evaluate the long-term effectiveness, safety, and patient satisfaction associated with sacral neuromodulation using the InterStim™ system in adults treated for lower urinary tract dysfunction at Fundación Santa Fe de Bogotá. The study will include patients who underwent definitive InterStim implantation between January 2010 and June 2026 for conditions including overactive bladder, urgency urinary incontinence, non-obstructive acontractile detrusor, or non-obstructive urinary retention.
Clinical information before implantation, details of the procedure, complications, reinterventions, device replacements, and explantations will be obtained retrospectively from medical records. Patients who can be contacted will also complete a single telephone follow-up assessment to evaluate current urinary symptoms, perceived improvement, satisfaction with treatment, catheter use, and current device status.
The study aims to describe the long-term effectiveness and safety of InterStim therapy in a Colombian population, including changes in urinary incontinence, patient-reported improvement and satisfaction, complications, therapeutic failure, and device survival.
This is an observational analytical retrospective cohort study with a single cross-sectional follow-up assessment. The study will include adult patients who underwent definitive implantation of the InterStim™ sacral neuromodulation system at Hospital Universitario Fundación Santa Fe de Bogotá between January 1, 2010, and June 30, 2026, for lower urinary tract dysfunction, including overactive bladder, urgency urinary incontinence, non-obstructive acontractile detrusor, and non-obstructive urinary retention.
Eligible patients will be identified consecutively using available institutional sources, including surgical scheduling records, procedure codes, and implantable device records. Data will be obtained from two sources: retrospective review of electronic medical records and a single telephone follow-up assessment.
Medical record review will include sociodemographic and clinical characteristics, indication for sacral neuromodulation, previous treatments, available pre-implantation patient-reported outcome measures, procedural characteristics, perioperative complications, reprogramming, reinterventions, device replacements, explantations, and other events occurring during follow-up.
During the single telephone follow-up, contactable patients who agree to participate will complete the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF), the Patient Global Impression of Improvement (PGI-I), and a 5-point Likert satisfaction scale. Current device status, catheter use, and additional urinary medications will also be recorded.
Effectiveness will be assessed using patient-reported urinary outcomes, including change in ICIQ-UI SF score when a pre-implantation score is available, with a reduction of at least 4 points considered clinically meaningful improvement. The PGI-I will provide an assessment of perceived improvement regardless of the availability of a baseline questionnaire. Additional effectiveness outcomes will include complete continence among patients with overactive bladder or urgency urinary incontinence and catheter independence among patients with non-obstructive urinary retention.
Safety outcomes will include perioperative and postoperative complications, classified according to the Clavien-Dindo classification, as well as reinterventions, device replacement, and surgical explantation. Device outcomes will include the frequency and causes of replacement or explantation and replacement- or explant-free device survival at 1, 3, 5, and 10 years.
Follow-up time will vary according to the date of definitive implantation and will extend from the index implantation date to the telephone assessment for patient-reported outcomes, or to the last available medical record information, definitive explantation, or death, as applicable for safety and device-survival outcomes.
Adults with lower urinary tract dysfunction who underwent definitive InterStim™ sacral neuromodulation implantation at Hospital Universitario Fundación Santa Fe de Bogotá between January 1, 2010, and June 30, 2026. The cohort includes patients treated for overactive bladder, urgency urinary incontinence, non-obstructive acontractile detrusor, or non-obstructive urinary retention. All eligible patients identified from institutional records during the study period will be included.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
InterStim™ implantation for at least one of the following conditions:- Overactive bladder.
Exclusion Criteria:
Group/Cohort Description \[\*\] Provide additional information about the group or cohort, including a description of any intervention(s) of interest.
Device: InterStim™ Sacral Neuromodulation System II - X
Sacral neuromodulation with the InterStim™ system. Participants included in this observational study previously underwent definitive InterStim implantation as part of their clinical care. The study does not assign or administer the device as a research intervention.
Change in Urinary Incontinence Severity Assessed by ICIQ-UI SF
Change in International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF) score from the pre-implantation score documented in the medical record to the score obtained at the single follow-up assessment. A reduction of ≥4 points will be considered a clinically meaningful improvement.
Time frame: From pre-implantation to the single follow-up assessment, approximately 6 months to 17 years after implantation.
Patient Global Impression of Improvement (PGI-I)
Patient-reported improvement in urinary condition assessed using the 7-point Patient Global Impression of Improvement (PGI-I) scale. A favorable response will be defined as "very much better" or "much better."
Time frame: At the single follow-up assessment, approximately 6 months to 17 years after implantation.
Patient Satisfaction With InterStim
Overall patient satisfaction with InterStim sacral neuromodulation assessed using a 5-point Likert scale.
Time frame: At the single follow-up assessment, approximately 6 months to 17 years after implantation.
Complete Urinary Continence
Proportion of patients with overactive bladder or urgency urinary incontinence who achieve complete urinary continence ("dry") following InterStim implantation.
Time frame: At the single follow-up assessment, approximately 6 months to 17 years after implantation.
Catheter Independence
Proportion of patients with non-obstructive urinary retention who achieve independence from intermittent catheterization following InterStim implantation.
Time frame: At the single follow-up assessment, approximately 6 months to 17 years after implantation.
Incidence of InterStim-Related Complications
Proportion of patients experiencing perioperative or postoperative complications following InterStim implantation. Complications will be classified according to the Clavien-Dindo classification.
Time frame: From implantation through the end of available follow-up, up to approximately 17 years.
Time to First Complication
Time from definitive InterStim implantation to the first documented complication.
Time frame: From implantation through the end of available follow-up, up to approximately 17 years.
Device Replacement or Explantation
Proportion of patients requiring InterStim device replacement or surgical explantation and the documented reasons for replacement or explantation.
Time frame: From implantation through the end of available follow-up, up to approximately 17 years.
Therapeutic Failure
Proportion of patients meeting the protocol-defined composite therapeutic failure endpoint: device explantation or permanent deactivation due to lack of efficacy; less than a 4-point reduction in ICIQ-UI SF among patients with an available pre-implantation score or PGI-I indicating "no change" or worse; or persistent need for intermittent catheterization among patients with non-obstructive urinary retention.
Time frame: At the single follow-up assessment and through the end of available follow-up, up to approximately 17 years.
Plan to share: No
Start is estimated for Dec 2026; primary completion for May 2027, 5 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundación Santa Fe de Bogota